Szu-Ying Tsai1,2, Yen-Wen Wu3,4,5, Shan-Ying Wang1,6, Yu-Chien Shiau1, Kuan-Ming Chiu7, Hao-Yuan Tsai8, Chien-Lin Lee8, Jung-Cheng Hsu8, Chung-Ming Tu8, Heng-Hsu Lin8, Shan-Hui Huang8. 1. Department of Nuclear Medicine, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist, New Taipei City, 220, Taiwan. 2. Ministry of Health and Welfare Nantou Hospital, Nantou County, Taiwan. 3. Department of Nuclear Medicine, Far Eastern Memorial Hospital, No. 21, Sec. 2, Nanya S. Rd., Banciao Dist, New Taipei City, 220, Taiwan. wuyw0502@gmail.com. 4. Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. wuyw0502@gmail.com. 5. National Yang-Ming University School of Medicine, Taipei, Taiwan. wuyw0502@gmail.com. 6. Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, Taipei, Taiwan. 7. Division of Cardiovascular Surgery, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan. 8. Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan.
Abstract
PURPOSE: Dynamic 18F-fluorodeoxyglucose (FDG) PET can be used to quantitatively assess the rate of myocardial glucose uptake (MRGlu). The aim of this study was to evaluate the clinical significance and prognostic value of right ventricular (RV) MRGlu in patients with coronary artery disease and heart failure with reduced ejection fraction. METHODS: Patients with left ventricular ejection fraction (LVEF) ≤ 40% were consecutively enrolled for FDG PET between November 2012 and May 2017. Global LV and RV MRGlu (μmol/min/100 g) were analyzed. Outcome events were independently assessed using electronic medical records to determine hospitalization for revascularization, new-onset ischemic events, heart failure, cardiovascular, and all-cause death. Differences between LV and RV MRGlu and associations with clinical characteristics and echocardiographic data were evaluated. Associations among FDG PET findings and outcomes were analyzed using Kaplan-Meier survival analysis. RESULTS: Seventy-five patients (mean age 62.2 ± 12.7 years, male 85.3%, LVEF 19.3 ± 8.6%) were included for analysis. The mean glucose utilization ratio of RV-to-LV (RV/LV MRGlu) was 89.5 ± 264.9% (r = 0.77, p < 0.001). Positive correlations between RV MRGlu and maximal tricuspid regurgitation peak gradient (r = 0.28, p = 0.033) and peak tricuspid regurgitation jet velocity (r = 0.29, p = 0.021) were noted. LVEF was positively correlated with LV MRGlu (r = 0.27, p = 0.018), but negatively correlated with end-diastolic volume (r = - 0.37, p = 0.001), end-systolic volume (r = - 0.54, p < 0.001), and RV/LV MRGlu (r = - 0.40, p < 0.001). However, RV MRGlu was not well correlated with LVEF. Forty-three patients received revascularization procedures after FDG PET, and 13 patients died in a mean follow-up period of 496 ± 453 days (1-1788 days), including nine cardiovascular deaths. Higher RV and LV MRGlu values, LVEF ≤ 16% and LV end-diastolic volume ≥ 209 ml of gated-PET were associated with poor overall survival and cardiac outcomes. CONCLUSIONS: In patients with coronary artery disease and ischemic cardiomyopathy, RV glucose utilization was positively correlated with RV pressure overload, but not LVEF. Global LV and RV MRGlu, LVEF, and LV end-diastolic volume showed significant prognostic value.
PURPOSE: Dynamic 18F-fluorodeoxyglucose (FDG) PET can be used to quantitatively assess the rate of myocardial glucose uptake (MRGlu). The aim of this study was to evaluate the clinical significance and prognostic value of right ventricular (RV) MRGlu in patients with coronary artery disease and heart failure with reduced ejection fraction. METHODS:Patients with left ventricular ejection fraction (LVEF) ≤ 40% were consecutively enrolled for FDG PET between November 2012 and May 2017. Global LV and RV MRGlu (μmol/min/100 g) were analyzed. Outcome events were independently assessed using electronic medical records to determine hospitalization for revascularization, new-onset ischemic events, heart failure, cardiovascular, and all-cause death. Differences between LV and RV MRGlu and associations with clinical characteristics and echocardiographic data were evaluated. Associations among FDG PET findings and outcomes were analyzed using Kaplan-Meier survival analysis. RESULTS: Seventy-five patients (mean age 62.2 ± 12.7 years, male 85.3%, LVEF 19.3 ± 8.6%) were included for analysis. The mean glucose utilization ratio of RV-to-LV (RV/LV MRGlu) was 89.5 ± 264.9% (r = 0.77, p < 0.001). Positive correlations between RV MRGlu and maximal tricuspid regurgitation peak gradient (r = 0.28, p = 0.033) and peak tricuspid regurgitation jet velocity (r = 0.29, p = 0.021) were noted. LVEF was positively correlated with LV MRGlu (r = 0.27, p = 0.018), but negatively correlated with end-diastolic volume (r = - 0.37, p = 0.001), end-systolic volume (r = - 0.54, p < 0.001), and RV/LV MRGlu (r = - 0.40, p < 0.001). However, RV MRGlu was not well correlated with LVEF. Forty-three patients received revascularization procedures after FDG PET, and 13 patients died in a mean follow-up period of 496 ± 453 days (1-1788 days), including nine cardiovascular deaths. Higher RV and LV MRGlu values, LVEF ≤ 16% and LV end-diastolic volume ≥ 209 ml of gated-PET were associated with poor overall survival and cardiac outcomes. CONCLUSIONS: In patients with coronary artery disease and ischemic cardiomyopathy, RV glucose utilization was positively correlated with RV pressure overload, but not LVEF. Global LV and RV MRGlu, LVEF, and LV end-diastolic volume showed significant prognostic value.
Entities:
Keywords:
18F-fluorodeoxyglucose; Heart failure; Positron emission tomography; Rate of myocardial glucose uptake; Right ventricle
Authors: Cathelijne E E van der Bruggen; Ryan J Tedford; Martin Louis Handoko; Jolanda van der Velden; Frances S de Man Journal: Cardiovasc Res Date: 2017-10-01 Impact factor: 10.787
Authors: Hiroshi Ohira; Robert deKemp; Elena Pena; Ross A Davies; Duncan J Stewart; George Chandy; Vladimir Contreras-Dominguez; Carole Dennie; Brian Mc Ardle; Ran Mc Klein; Jennifer M Renaud; Jean N DaSilva; Carolyn Pugliese; Rosemary Dunne; Rob Beanlands; Lisa M Mielniczuk Journal: Eur Heart J Cardiovasc Imaging Date: 2015-06-09 Impact factor: 6.875
Authors: Henning Gall; Janine F Felix; Franziska K Schneck; Katrin Milger; Natascha Sommer; Robert Voswinckel; Oscar H Franco; Albert Hofman; Ralph T Schermuly; Norbert Weissmann; Friedrich Grimminger; Werner Seeger; Hossein A Ghofrani Journal: J Heart Lung Transplant Date: 2017-02-17 Impact factor: 10.247
Authors: Evan L Hardegree; Arun Sachdev; Eric R Fenstad; Hector R Villarraga; Robert P Frantz; Michael D McGoon; Jae K Oh; Naser M Ammash; Heidi M Connolly; Benjamin W Eidem; Patricia A Pellikka; Garvan C Kane Journal: Circ Heart Fail Date: 2013-05-24 Impact factor: 8.790
Authors: Arun Abraham; Malek Kass; Terrence D Ruddy; Robert A deKemp; Andrea K Y Lee; Michael C Ling; Andrew Ha; Rob S Beanlands; Benjamin J W Chow Journal: J Nucl Cardiol Date: 2009-10-14 Impact factor: 5.952
Authors: Yang Zuo; Ramsey D Badawi; Cameron C Foster; Thomas Smith; Javier E López; Guobao Wang Journal: IEEE Trans Radiat Plasma Med Sci Date: 2020-10-15